Oscar Health, Inc. (OSCR) is a publicly traded company in the Healthcare — Medical - Healthcare Plans industry listed on NYSE. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Oscar Health, Inc. operates as a health insurance provider across the United States. Its offerings include various health plans such as those for individuals and families, small businesses, and Medicare Advantage options. The company also features "+Oscar," a proprietary technology platform designed to facilitate engagement between healthcare providers, payers, and their members or patients. Additionally, Oscar Health provides reinsurance solutions.
Is Oscar Health, Inc. stock overvalued or undervalued in 2026?
Oscar Health, Inc. (OSCR) trades at 21.7× earnings (P/E), below the median of the 246 healthcare companies over $2bn in Kaplio's universe. At its sector median (30.4×) $43 (+40 %).
Kaplio overview: Oscar Health, Inc.
Market cap $8B · 52 weeks $11 – $34 (12 % below the high) · P/E 21.7× · 2027 expected P/E 12.7× · Dividend none · Next earnings November 5, 2026 · expected EPS $-0.14 · Closing price, Oct 30 · accounts published Aug 6.
- Valuation: P/E 21.7× (cheap).
- Business: ROIC 23 % (fair).
- Balance sheet: Net debt/EBITDA 6.0× (fragile).
- Earnings: 5 of 8 (uneven).
What would it be worth at its usual multiples?
At its sector median (30.4×) $43 (+40 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
P/E calculated by Kaplio with 12-month GAAP earnings; the data provider reports 17.8×.
What matters in pharma: 1 of 4 pass
- R&D / Revenue 0.0 %, fails.
- Gross margin 14.4 %, fails.
- Net debt / EBITDA 6.0×, fails.
- ROIC 23.0 %, passes.
Against its peers (reference peers) — Oscar Health, Inc.: P/E 21.7×; EV/EBITDA 6.7×; ROIC 23.0 %; $7.9B. Molina Healthcare, Inc. (P/E —; EV/EBITDA 30.5×; ROIC 2.1 %; $10.7B), Centene Corp. (P/E 23.4×; EV/EBITDA 7.6×; ROIC 2.2 %; $33.9B), Cigna Corporation (P/E 12.3×; EV/EBITDA 8.3×; ROIC 7.7 %; $78.8B).
Profitability
| Return on Equity | 38.53% |
| Return on Invested Capital | 22.98% |
| Return on Assets | 4.91% |
| Gross Margin | 44.93% |
| Operating Margin | 4.07% |
| Net Margin | 3.60% |
Financial Health
| Debt / Equity | 0.21 |
| Current Ratio | 1.08 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 1.29 |
Price Performance
| 1 month | -1.84% |
| 3 months | -1.20% |
| Year-to-date | +111.34% |
| 1 year | +68.72% |
| 3 years | +451.18% |
| 5 years | +79.81% |
Related companies: CLOV · CVS · CI · ELV · CNC · MOH
Explore sector: Healthcare · Medical - Healthcare Plans
More sections of OSCR: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks